

Rogério A Lobo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3100558/publications.pdf>

Version: 2024-02-01

99
papers

9,134
citations

61984

43
h-index

51608

86
g-index

102
all docs

102
docs citations

102
times ranked

6837
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. <i>Fertility and Sterility</i> , 2012, 97, 28-38.e25.	1.0	1,494
2	Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1159-1168.	3.6	851
3	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1897-1899.	3.6	417
4	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 167, 1807-1812.	1.3	399
5	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS Cognitive and Affective Study. <i>PLoS Medicine</i> , 2015, 12, e1001833.	8.4	330
6	CLINICAL REVIEW 27 Effects of Hormonal Replacement on Lipids and Lipoproteins in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 925-930.	3.6	292
7	Potential Options for Preservation of Fertility in Women. <i>New England Journal of Medicine</i> , 2005, 353, 64-73.	27.0	247
8	Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. <i>Fertility and Sterility</i> , 2009, 92, 1025-1038.	1.0	239
9	The Importance of Diagnosing the Polycystic Ovary Syndrome. <i>Annals of Internal Medicine</i> , 2000, 132, 989.	3.9	236
10	Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. <i>Fertility and Sterility</i> , 2003, 79, 1341-1352.	1.0	230
11	Metabolic syndrome after menopause and the role of hormones. <i>Maturitas</i> , 2008, 60, 10-18.	2.4	224
12	Estrogen and progestogen use in postmenopausal women. <i>Menopause</i> , 2008, 15, 584-602.	2.0	211
13	The diagnosis of polycystic ovary syndrome in adolescents. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 201.e1-201.e5.	1.3	205
14	Prevention of diseases after menopause. <i>Climacteric</i> , 2014, 17, 540-556.	2.4	197
15	Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. <i>Fertility and Sterility</i> , 2001, 76, 13-24.	1.0	188
16	A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. <i>Fertility and Sterility</i> , 1993, 60, 664-667.	1.0	183
17	Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 393-397.	3.6	175
18	Insulin resistance in polycystic ovary syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 1983, 147, 588-592.	1.3	174

#	ARTICLE	IF	CITATIONS
19	Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. American Journal of Medicine, 2006, 119, 356.e1-356.e6.	1.5	145
20	Clinical and laboratory predictors of clomiphene response**Supported in part by Grant HD 05932 from the National Institutes of Health, United States Public Health Service, Bethesda, Maryland, and by a grant from the Ford Foundation.. Fertility and Sterility, 1982, 37, 168-174.	1.0	143
21	The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility, 2004, 81, 1498-1501.	1.0	141
22	Prolactin modulation of dehydroepiandrosterone sulfate secretion. American Journal of Obstetrics and Gynecology, 1980, 138, 632-636.	1.3	115
23	Surgical menopause and cardiovascular risks. Menopause, 2007, 14, 562-566.	2.0	112
24	Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis, 2016, 254, 282-290.	0.8	105
25	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	2.0	97
26	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1897-1899.	3.6	94
27	Do hyperandrogenic women with normal menses have polycystic ovary syndrome?. Fertility and Sterility, 1999, 71, 319-322.	1.0	90
28	Polycystic ovaries in hirsute women with normal menses. American Journal of Medicine, 2001, 111, 602-606.	1.5	90
29	Where Are We 10 Years After the Women's Health Initiative?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1771-1780.	3.6	89
30	Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertility and Sterility, 2004, 82, 391-397.	1.0	86
31	Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 995-1000.	3.6	82
32	Evaluation of Cardiovascular Event Rates With Hormone Therapy in Healthy, Early Postmenopausal Women. Archives of Internal Medicine, 2004, 164, 482.	3.8	77
33	A disorder without identity: HCA, PCO, PCOD, PCOS, SLS. What are we to call it?!. Fertility and Sterility, 1995, 63, 1158-1160.	1.0	73
34	A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertility and Sterility, 2006, 86, 1669-1675.	1.0	69
35	The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertility and Sterility, 1994, 62, 1176-1180.	1.0	65
36	A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clinical Endocrinology, 2002, 57, 231-234.	2.4	63

#	ARTICLE	IF	CITATIONS
37	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. JAMA Internal Medicine, 2017, 177, 1471.	5.1	59
38	6 Peripheral androgens and the role of androstenediol glucuronide. Clinics in Endocrinology and Metabolism, 1986, 15, 293-306.	1.6	57
39	Alterations in low-density lipoprotein and high-density lipoprotein subclasses among hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertility and Sterility, 1999, 72, 990-995.	1.0	53
40	Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertility and Sterility, 1996, 65, 1100-1109.	1.0	52
41	A 17 β -Estradiol + Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women. Obstetrics and Gynecology, 2018, 132, 161-170.	2.4	48
42	Is 11 β -hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?. American Journal of Obstetrics and Gynecology, 1991, 165, 1837-1842.	1.3	45
43	Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. Fertility and Sterility, 1999, 72, 926-931.	1.0	45
44	Amh Measurement Versus Ovarian Ultrasound In The Diagnosis Of Polycystic Ovary Syndrome In Different Phenotypes. Endocrine Practice, 2016, 22, 287-293.	2.1	38
45	Menopausal Sexual Interest Questionnaire (MSIQ): A Unidimensional Scale for the Assessment of Sexual Interest in Postmenopausal Women. Journal of Sex and Marital Therapy, 2004, 30, 235-250.	1.5	37
46	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology, 2022, 15, 121-137.	3.1	33
47	A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause, 2020, 27, 848-857.	2.0	30
48	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. Menopause, 2011, 18, 237-240.	2.0	30
49	Ovulation Induction in Clomiphene-Resistant Anovulatory Women: Differential Follicular Response to Purified Urinary Follicle-Stimulating Hormone (FSH) Versus Purified Urinary FSH and Luteinizing Hormone*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 922-927.	3.6	29
50	Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiological Genomics, 2013, 45, 79-88.	2.3	28
51	The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne. Journal of Endocrinological Investigation, 2002, 25, 765-768.	3.3	27
52	Endocrinology: Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation*. Human Reproduction, 1995, 10, 524-528.	0.9	26
53	Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology, 2004, 191, 1580-1584.	1.3	26
54	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine, 2012, 42, 526-534.	2.3	26

#	ARTICLE	IF	CITATIONS
55	What are the key features of importance in polycystic ovary syndrome?. <i>Fertility and Sterility</i> , 2003, 80, 259-261.	1.0	24
56	Lipids, clotting factors, and diabetes: Endogenous risk factors for cardiovascular disease. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 158, 1584-1591.	1.3	23
57	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , 2016, 48, 33-41.	2.3	23
58	Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac003.	0.2	23
59	Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?. <i>Fertility and Sterility</i> , 2012, 98, 1043-1046.	1.0	21
60	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. <i>Menopause</i> , 2011, 18, 237-40.	2.0	21
61	Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. <i>Clinical Endocrinology</i> , 2019, 91, 553-560.	2.4	19
62	What is the cardioprotective role of hormone replacement therapy?. <i>Current Atherosclerosis Reports</i> , 2003, 5, 56-66.	4.8	16
63	Early ovarian ageing: a hypothesis: What is early ovarian ageing?. <i>Human Reproduction</i> , 2003, 18, 1762-1764.	0.9	16
64	The Rationale for Low-Dose Hormonal Therapy. <i>Endocrine</i> , 2004, 24, 217-222.	2.2	16
65	Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function. <i>Gynecological Endocrinology</i> , 2018, 34, 301-304.	1.7	16
66	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R912-R920.	1.8	15
67	Formulations and Use of Androgens in Women. <i>Mayo Clinic Proceedings</i> , 2004, 79, S3-S7.	3.0	13
68	Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 526.e1-526.e7.	1.3	12
69	Menopause and Aging. , 2019, , 322-356.e9.		12
70	Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. <i>Climacteric</i> , 2019, 22, 610-616.	2.4	12
71	Kisspeptin Influence on Polycystic Ovary Syndrome – a Mini Review. <i>Reproductive Sciences</i> , 2020, 27, 455-460.	2.5	12
72	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. <i>Current Atherosclerosis Reports</i> , 2002, 4, 52-58.	4.8	11

#	ARTICLE	IF	CITATIONS
73	Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 383-391.	2.3	11
74	Priorities in polycystic ovary syndrome. <i>Medical Journal of Australia</i> , 2001, 174, 554-555.	1.7	10
75	Laboratory Assessment. , 2014, , 822-850.e3.		10
76	Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. <i>Maturitas</i> , 2005, 51, 98-109.	2.4	9
77	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
78	Menopause and Aging. , 2009, , 325-355.		6
79	Evaluation of Hormonal Status. , 2009, , 801-823.		6
80	Low estradiol responses in oocyte donors undergoing gonadotropin stimulation do not influence clinical outcomes. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1675-1682.	2.5	6
81	Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and) Tj ETQq1 1 0.784314 rgBT /@verlock		6
82	Should symptomatic menopausal women be offered hormone therapy?. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 40.	0.2	6
83	Menopause and Aging. , 2014, , 308-339.e8.		5
84	Utility of Ovarian Reserve Screening with Anti-Müllerian Hormone for Reproductive Age Women Deferring Pregnancy. <i>Journal of Women's Health</i> , 2017, 26, 345-351.	3.3	4
85	Outcomes of high-order multiple implantations in women undergoing ovum donation. , 1997, 6, 268-272.		3
86	Differences in Urinary Excretion Patterns of the hLH Beta Core Fragment in Premenopausal, Perimenopausal, and Postmenopausal Women. <i>Menopause</i> , 1999, 6, 290-298.	2.0	3
87	Potential pitfalls of reproductive direct-to-consumer testing. <i>F&S Reports</i> , 2022, 3, 3-7.	0.7	2
88	Views on Recent Trials and the Future of Hormonal Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2004, 47, 424-427.	1.1	1
89	FOREWORD. <i>Clinical Obstetrics and Gynecology</i> , 2008, 51, 533.	1.1	1
90	Daniel R. Mishell Jr, MD, May 7, 1931â€“May 4, 2016. <i>Climacteric</i> , 2016, 19, 411-412.	2.4	1

#	ARTICLE	IF	CITATIONS
91	Use of anti-AMH/4llarian hormone testing during ovarian reserve screening to identify women at risk of polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2016, 135, 73-76.	2.3	1
92	The Future of Therapy and the Role of Hormone Therapy. , 2007, , 875-880.		1
93	Should symptomatic menopausal women be offered hormone therapy?. MedGenMed: Medscape General Medicine, 2006, 8, 1 p preceding 35.	0.2	1
94	Outcomes of High-Order Multiple Implantations in Women Undergoing Ovum Donation. Journal of Maternal-Fetal and Neonatal Medicine, 1997, 6, 268-272.	1.5	0
95	Areas for future inquiry. Endocrinology and Metabolism Clinics of North America, 2004, 33, 761-769.	3.2	0
96	Menopausal Hormonal Therapy and Cardiovascular Disease. Current Obstetrics and Gynecology Reports, 2014, 3, 217-222.	0.8	0
97	Foreword. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 3.	2.5	0
98	Formulations and use of androgens in women. Mayo Clinic Proceedings, 2004, 79, S3-7.	3.0	0
99	Climacteric commentaries. Endogenous estradiol and coronary calcifications in postmenopausal women. Climacteric, 2010, 13, 502-3.	2.4	0